1. any exposure to investigational medications targeting covid-19 during the present disease. these include recently approves antibodies (passive immunization) for treatment of covid-19. 2. use of famotidine within the last 30 days for any indication, e.g. medicating gastric ulcer or recent off label use for covid-19. 3. severe covid-19 disease at time of enrollment requiring admission to hospital. 4. history of stage 3 severe chronic kidney disease, i.e. egfr of \< 60ml/min. 5. allergy to famotidine or non-medical ingredients of the study tablet. 6. known to be immunocompromised by treatment for existing disease due to the immunomodulatory effects of famotidine and therefore possible effects on the pre- existing disease or the immunosuppressive therapy. 7. patients currently using tizanidine. 8. documented deficiency of any of the following minerals: al, cu, mn, fe and zn. 9. inability to perform the tasks required for the patient reported outcome measure recordings, including but not restricted to limited language proficiency. 10. have symptoms of dysphagia or inability to swallow size #000 capsules.

1. any exposure to investigational medications targeting covid-19 during the present disease. these include recently approves antibodies (passive immunization) for treatment of covid-19. 2. use of famotidine within the last 30 days for any indication, e.g. medicating gastric ulcer or recent off label use for covid-19. 3. severe covid-19 disease at time of enrollment requiring admission to hospital. 4. history of stage 3 severe chronic kidney disease, i.e. egfr of \< 60ml/min. 5. allergy to famotidine or non-medical ingredients of the study tablet. 6. known to be immunocompromised by treatment for existing disease due to the immunomodulatory effects of famotidine and therefore possible effects on the pre- existing disease or the immunosuppressive therapy. 7. patients currently using tizanidine. 8. documented deficiency of any of the following minerals: al, cu, mn, fe and zn. 9. inability to perform the tasks required for the patient reported outcome measure recordings, including but not restricted to limited language proficiency. 10. have symptoms of dysphagia or inability to swallow size #000 capsules.

any exposure to investigational medications targeting covid-19 during the present disease. these include recently approves antibodies (passive immunization) for treatment of covid-19. use of famotidine within the last 30 days for any indication, e.g. medicating gastric ulcer or recent off label use for covid-19. severe covid-19 disease at time of enrollment requiring admission to hospital. history of stage 3 severe chronic kidney disease, i.e. egfr of < 60ml/min. allergy to famotidine or non-medical ingredients of the study tablet. known to be immunocompromised by treatment for existing disease due to the immunomodulatory effects of famotidine and therefore possible effects on the pre- existing disease or the immunosuppressive therapy. patients currently using tizanidine. documented deficiency of any of the following minerals: al, cu, mn, fe and zn. inability to perform the tasks required for the patient reported outcome measure recordings, including but not restricted to limited language proficiency. have symptoms of dysphagia or inability to swallow size #000 capsules.

any exposure to investigational medications targeting covid-19 during the present disease. these include recently approves antibodies (passive immunization) for treatment of covid-19. use of famotidine within the last 30 days for any indication, e.g. medicating gastric ulcer or recent off label use for covid-19. severe covid-19 disease at time of enrollment requiring admission to hospital. history of stage 3 severe chronic kidney disease, i.e. egfr of < 60ml/min. allergy to famotidine or non-medical ingredients of the study tablet. known to be immunocompromised by treatment for existing disease due to the immunomodulatory effects of famotidine and therefore possible effects on the pre- existing disease or the immunosuppressive therapy. patients currently using tizanidine. documented deficiency of any of the following minerals: al, cu, mn, fe and zn. inability to perform the tasks required for the patient reported outcome measure recordings, including but not restricted to limited language proficiency. have symptoms of dysphagia or inability to swallow size #000 capsules.

1. any exposure to investigational medications targeting covid-19 during the present disease. these include recently approves antibodies (passive immunization) for treatment of covid-19. 2. use of famotidine within the last 30 days for any indication, e.g. medicating gastric ulcer or recent off label use for covid-19. 3. severe covid-19 disease at time of enrollment requiring admission to hospital. 4. history of stage 3 severe chronic kidney disease, i.e. egfr of < 60ml/min. 5. allergy to famotidine or non-medical ingredients of the study tablet. 6. known to be immunocompromised by treatment for existing disease due to the immunomodulatory effects of famotidine and therefore possible effects on the pre- existing disease or the immunosuppressive therapy. 7. patients currently using tizanidine. 8. documented deficiency of any of the following minerals: al, cu, mn, fe and zn. 9. inability to perform the tasks required for the patient reported outcome measure recordings, including but not restricted to limited language proficiency. 10. have symptoms of dysphagia or inability to swallow size #000 capsules.

1. any exposure to investigational medications targeting covid-19 during the present disease. these include recently approves antibodies (passive immunization) for treatment of covid-19. 2. use of famotidine within the last 30 days for any indication, e.g. medicating gastric ulcer or recent off label use for covid-19. 3. severe covid-19 disease at time of enrollment requiring admission to hospital. 4. history of stage 3 severe chronic kidney disease, i.e. egfr of < 60ml/min. 5. allergy to famotidine or non-medical ingredients of the study tablet. 6. known to be immunocompromised by treatment for existing disease due to the immunomodulatory effects of famotidine and therefore possible effects on the pre- existing disease or the immunosuppressive therapy. 7. patients currently using tizanidine. 8. documented deficiency of any of the following minerals: al, cu, mn, fe and zn. 9. inability to perform the tasks required for the patient reported outcome measure recordings, including but not restricted to limited language proficiency. 10. have symptoms of dysphagia or inability to swallow size #000 capsules.